Retrospective multicentric survival analysis of patients receiving TPEx regimen as first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma
Median OS of 17.9 months under TPEx as first-line treatment of R/M HNSCC compares favorably with historical data. IO exposure after progression on TPEx was the rule.
Authors
- Émilie Lévêque (ORCID: https://orcid.org/0000-0001-6741-2518)
- Cosmin Moldovan (ORCID: https://orcid.org/0000-0003-1362-6427)
- Audrey Rambeau (ORCID: https://orcid.org/0000-0003-0241-4453)
- C. Even
- Ludivine Libert (ORCID: https://orcid.org/0000-0002-3382-1273)
- Y. Pointreau
- Cyril Abdeddaim
- Emeline Guiard (ORCID: https://orcid.org/0000-0001-9120-8269)
- Sophie Duplomb
- Florian Clatot (ORCID: https://orcid.org/0000-0002-7074-9282)
- Khalid Saleh (ORCID: https://orcid.org/0000-0003-3816-2518)
- Julien Dubreuil (ORCID: https://orcid.org/0000-0003-2735-9534)
- N Olympios-Gerotzortzos
Institutions
- Institut Gustave Roussy (FR)
- Hospices Civils de Lyon (FR)
- Centre François Baclesse (FR)
- Centre Jean Bernard (FR)
- Centre Oscar Lambret (FR)
- Centre Virchow-Villermé (FR)
- Centre Hospitalier Universitaire de Rouen (FR)
- Centre Henri Becquerel (FR)
- Université de Rouen Normandie (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104544
- Citations
- 3
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.54